Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.77 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.77 |
| ▸ | STAT3 | P40763 | 1/20 | 0.61 |
| ▸ | CCNK | O75909 | 1/20 | 0.57 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | CDK9 | P50750 | 1/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL1B | P01584 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19692297 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL30305312 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL19692453 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL29842899 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL22959658 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL23832857 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL19692342 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL30305317 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL19692300 | 0.99 | CRBN (0.78) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL30275753 | 0.99 | CRBN (0.78) | CRBNDDB1STAT3CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598914-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | Tocris Cookson Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| US-12318452-B2 | Degraders of WEE1 kinase | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| WO-2024102970-A1 | COMPOUNDS FOR MODULATING SYK ACTIVITY AND E3 UBIQUITIN LIGASE ACTIVITY | Kronos Bio, Inc. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024074848-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LIMITED (GB) | 2024-04-11 | — | — | WO | disclosed |
| US-20220175722-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220153722-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220047709-A1 | DEGRADERS OF WEE1 KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220047709-A1 | DEGRADERS OF WEE1 KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3947368-A1 | CDK2/5 DEGRADERS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3787747-A1 | SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) | Dana-Farber Cancer Institute, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| WO-2020206137-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020206137-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-10689366-B2 | Compounds for MALT1 degredation | CORNELL UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689366-B2 | Compounds for MALT1 degredation | CORNELL UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2020069105-A1 | DEGRADERS OF WEE1 KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-3535254-A1 | COMPOUNDS FOR MALT1 DEGRADATION | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190263785-A1 | COMPOUNDS FOR MALT1 DEGRADATION | CORNELL UNIVERSITY (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263785-A1 | COMPOUNDS FOR MALT1 DEGRADATION | CORNELL UNIVERSITY (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175722-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | FGFR2, FGF2, FGFR1 | CRBN 801/4885DDB1 2520/4885STAT3 793/4885 |
| US-10689366-B2 | Compounds for MALT1 degredation | CRBN, NFKB2, NFKB1 | CRBN 1/4885DDB1 63/4885STAT3 1185/4885 |
| US-20190263785-A1 | COMPOUNDS FOR MALT1 DEGRADATION | CRBN, NFKB2, NFKB1 | CRBN 1/4885DDB1 72/4885STAT3 1020/4885 |
| US-20220047709-A1 | DEGRADERS OF WEE1 KINASE | WEE1, WEE2, PPME1 | CRBN 553/4885DDB1 1060/4885STAT3 2042/4885 |
| US-12318452-B2 | Degraders of WEE1 kinase | WEE1, WEE2, PPME1 | CRBN 553/4885DDB1 1060/4885STAT3 2042/4885 |
| US-20220153722-A1 | CDK2/5 DEGRADERS AND USES THEREOF | CDK2, CDK5, CDK5R1 | CRBN 277/4885DDB1 263/4885STAT3 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.